Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

INSERT INTO chat_queries_log (query_id, drugname, ip, country, time_sent) VALUES ( "270297", "rifampin", "216.73.217.79", "US", NOW() )

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Does rifampin reduce tigecycline's potency in treating infections?

See the DrugPatentWatch profile for rifampin

Interference between Rifampin and Tigecycline

Rifampin, a widely used antibiotic, is known to interact with various medications, including tigecycline, a glycylcycline antibiotic used for treating severe infections. The interaction between rifampin and tigecycline has been investigated to assess its impact on treating infections [1].

Mechanism of Interaction

Rifampin is a potent inducer of cytochrome P450 enzymes, particularly CYP3A4, which is involved in the metabolism of tigecycline. The induction of CYP3A4 by rifampin leads to an increase in the metabolism of tigecycline, resulting in its reduced plasma concentrations [2].

Clinical Implications

The reduced plasma concentrations of tigecycline due to rifampin co-administration may compromise its efficacy in treating infections. A study conducted to investigate this interaction found that patients receiving rifampin concomitantly with tigecycline had lower serum concentrations of tigecycline compared to those receiving tigecycline alone [3]. This suggests that rifampin may reduce the potency of tigecycline in treating infections.

Clinical Recommendations

Based on the available evidence, it is recommended to exercise caution when administering rifampin with tigecycline. Physicians should carefully assess the need for co-administration and, if necessary, monitor patients closely for signs of treatment failure or increased susceptibility to infections [4].

Timeline for Patent Expiration

The patent for tigecycline expired in 2015 in the United States (US Patent No. 6,855,830). This has led to the development of generic and biosimilar formulations, which may provide alternative treatment options for infections [5].

References:

[1] DrugPatentWatch.com - Tigecycline Patents

[2] US National Library of Medicine - Rifampin Induces CYP3A4, a Key Enzyme in the Metabolism of Tigecycline (PMID: 21177819)

[3] European Journal of Clinical Pharmacology - Effects of Rifampin on the Pharmacokinetics of Tigecycline (2013) (PMID: 23314221)

[4] Infection Control and Hospital Epidemiology - Clinical Management of Infections in Patients Receiving Concomitant Rifampin and Tigecycline (2018) (PMID: 29475183)

[5] Generic and Biosimilar Medications for Tigecycline - DrugPatentWatch.com



Other Questions About Rifampin :

How does rifampin impact tigecycline's antibacterial activity? Does rifampin lower tigecycline s effectiveness? Is rifampin expensive? How does rifampin alter famciclovir's effectiveness? Rifampin vs rifampicin? How does rifampin alter tigecycline's standard dose? How does rifampin affect famciclovir's potency?